Establishment and characterization of a new and stable collagen-binding assay for the assessment of von Willebrand factor activity

International Journal of Laboratory Hematology

Volumn 35, Issue 2, 2013, Pages 170-176

  Ni, Y ^a   Nesrallah, J ^a   Agnew, M ^a   Geske, F J ^a   Favaloro, E J ^b  

^a Precision BioLogic   (Canada)

^b WESTMEAD HOSPITAL   (Australia)

Author keywords

Collagen binding; ELISA; Ristocetin cofactor; Von Willebrand disease; Von Willebrand factor

Indexed keywords

VON WILLEBRAND FACTOR;

ACCURACY; ARTICLE; ASSAY; COLLAGEN BINDING ASSAY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LABORATORY DIAGNOSIS; LIMIT OF DETECTION; LIMIT OF QUANTITATION; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN BINDING; PROTHROMBIN TIME; SENSITIVITY AND SPECIFICITY; VON WILLEBRAND DISEASE;

CLINICAL CHEMISTRY TESTS; COLLAGEN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; SENSITIVITY AND SPECIFICITY; VON WILLEBRAND DISEASE, TYPE 1; VON WILLEBRAND DISEASE, TYPE 2; VON WILLEBRAND FACTOR;

EID: 84875050271     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/ijlh.12019     Document Type: Article

References (33)

1. Favaloro EJ. Von Willebrand disease: local diagnosis and management of a globally distributed bleeding disorder. Semin Thromb Hemost 2011a;37:440-55.
2. Bowman M, Hopman WM, Rapson D, Lillicrap D, James P. The prevalence of symptomatic von Willebrand disease in primary care practice. J Thromb Haemost 2010;8:213-6.
3. Castaman G, Federici AB, Rodeghiero F, Mannucci PM. von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment. Haematologica 2003;88:94-108.
4. Favaloro EJ. Laboratory assessment as a critical component of the appropriate diagnosis and sub-classification of von Willebrand's disease. Blood Rev 1999;13:185-204.
5. Hampshire DJ, Goodeve AC. The International Society on Thrombosis and Haematosis von Willebrand disease database: an update. Semin Thromb Hemost 2011;37:470-9.
6. Lillicrap D. Genotype/phenotype association in von Willebrand disease: is the glass half full or empty? J Thromb Haemost 2009;7(Suppl.1):65-70.
7. Sadler JE, Budde U, Eikenboom JCJ, Favaloro EJ, Hill FGH, Holmberg L, Ingerslev J, Lee CA, Lillicrap D, Mannucci PM, Mazurier C, Meyer D, Nichols WL, Nishino M, Peake IR, Rodeghiero F, Schneppenheim R, Ruggeri ZM, Srivastava A, Montgomery RR, Federici AB, the Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006;4:2103-14.
8. Adcock DM, Bethel M, Valcour A. Diagnosing von Willebrand disease: a large reference laboratory's perspective. Semin Thromb Hemost 2006;32:472-9.
9. Favaloro EJ, Bonar R, Kershaw G, Sioufi J, Baker R, Hertzberg M, Street A, Marsden K. Reducing errors in identification of von Willebrand disease: the experience of the Royal College of Pathologists of Australasia quality assurance program. Semin Thromb Hemost 2006;32:505-13.
10. Favaloro EJ. Diagnosis and classification of von Willebrand disease: a review of the differential utility of various functional von Willebrand factor assays. Blood Coagul Fibrinolysis 2011b;22:553-64.
11. Patzke J, Schneppenheim R. Laboratory diagnosis of von Willebrand disease. Hämostaseologie 2010;30:203-6.
12. Turecek PL, Siekmann J, Schwarz HP. Comparative study on collagen-binding enzyme-linked immunosorbent assay and ristocetin cofactor activity assays for detection of functional activity of von Willebrand factor. Semin Thromb Hemost 2002;28:149-60.
13. Favaloro EJ. An update on the von Willebrand factor collagen binding assay: 21 years of age and beyond adolescence but not yet a mature adult. Semin Thromb Hemost 2007;33:727-44.
14. Flood VH, Friedman KD, Gill JC, Morateck PA, Wren JS, Scott JP, Montgomery RR. Limitations of the ristocetin cofactor assay in measurement of von Willebrand factor function. J Thromb Haemost 2009;7:1832-9.
15. Baronciani L, Federici AB, Cozzi G, Canciani MT, Mannucci PM. von Willebrand factor collagen binding assay in von Willebrand disease type 2A, 2B, and 2M. J Thromb Haemost 2006;4:2088-90.
16. Casonato A, Pontara E, Bertomoro A, Sartorello F, Cattini MG, Girolami A. Von Willebrand factor collagen binding activity in the diagnosis of von Willebrand disease: an alternative to ristocetin co-factor activity? Br J Haematol 2000;112:578-83.
17. Favaloro EJ. Evaluation of commercial von Willebrand factor collagen binding assays to assist the discrimination of types 1 and 2 von Willebrand disease. Thromb Haemost 2010;104:1009-21.
18. Federici AB. Ristocetin cofactor and collagen binding activities normalized to antigen levels for a rapid diagnosis of Type 2 von Willebrand disease: single center comparison of four different assays. Thromb Haemost 2000;84:1127-8.
19. Kallas A, Talpsep T. The von Willebrand factor collagen-binding activity assay: clinical application. Ann Hematol 2001;80:466-71.
20. Paczuski R. Determination of von Willebrand factor activity with collagen-binding assay and diagnosis of von Willebrand disease: effect of collagen source and coating conditions. J Lab Clin Med 2002;140:250-4.
21. Popov J, Zhukov O, Ruden S, Zeschmann T, Sferruzza A, Sahud M. Performance and clinical utility of a commercial von Willebrand factor collagen binding assay for laboratory diagnosis of von Willebrand disease. Clin Chem 2006;52:1965-7.
22. Riddell AF, Jenkins PV, Nitu-Whalley IC, McCraw AH, Lee CA, Brown SA. Use of the collagen-binding assay for von Willebrand factor in the analysis of type 2M von Willebrand disease: a comparison with the ristocetin cofactor assay. Br J Haematol 2002;116:187-92.
23. Siekmann J, Turecek PL, Schwarz HP. The determination of von Willebrand factor activity by collagen binding assay. Hemophilia 1998;4(Suppl.3):15-24.
24. Chandler WL, Peerschke EI, Castellone DD, Meijer P, NASCOLA Proficiency Testing Committee. Von Willebrand factor assay proficiency testing. The North American Specialized Coagulation Laboratory Association experience. Am J Clin Pathol 2011;135:862-9.
25. Adcock DM, Hoefner DM, Kottke-Marchant K, Marlar RA, Szamosi DI, Warunek DJ Collection, transport, and processing of blood specimens for testing plasma-based coagulation assays and molecular hemostasis assays; approved guideline. H21-A5, Vol. 28, No.5; 2008.
26. Tholen DW, Kallner A, Kennedy JW, Krouwer JS, Meier K Evaluation of precision performance of quantitative measurement methods; approved guideline, 2nd edn. EP05-A2, Vol. 24, No. 25; 2004a.
27. Tholen DW, Linnet K, Kondratovich M, Armbruster DA, Garrett PE, Jones RL, Kroll MH, Lequin RM, Pankratz TJ, Scassellati GA, Schimmel H, Tsai J Protocols for determination of limits of detection and limits of quantitation; approved guideline. EP17-A, Vol. 24, No. 34; 2004b.
28. Tholen DW, Kroll M, Astles JR, Caffo AL, Happe TM, Krouwer J, Lasky F Evaluation of the linearity of quantitative measurement procedures: a statistical approach; approved guideline. EP06-A, Vol. 23, No. 16; 2003.
29. de Groot PG. The role of von Willebrand factor in platelet function. Semin Thromb Hemost 2002;28:133-8.
30. Romijn RA, Westein E, Bouma B, Schiphorst ME, Sixma JJ, Lenting PJ, Huizinga EG. Mapping the collagen-binding site in the von Willebrand factor-A3 domain. J Biol Chem 2003;278:15035-9.
31. Favaloro EJ. A duplex issue: (i) time to re-appraise the diagnosis and classification of von Willebrand disorder, and (ii) clarification of the roles of von Willebrand factor collagen binding and ristocetin cofactor activity assays. Haemophilia 2002;8:828-33.
32. Castaman G, Montgomery RR, Meschengieser SS, Haberichter SL, Woods AI, Lazzari MA. von Willebrand's disease diagnosis and laboratory issues. Haemophilia 2010;16(Suppl.5):67-73.
33. Favaloro EJ, Franchini M, Lippi G. Biological therapies for von Willebrand Disease. Expert Opin Biol Ther 2012;12:551-64.